Alexandra Balcom Sells 4,236 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom sold 4,236 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $97.32, for a total transaction of $412,247.52. Following the completion of the transaction, the chief financial officer directly owned 84,914 shares of the company’s stock, valued at approximately $8,263,830.48. The trade was a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alexandra Balcom also recently made the following trade(s):

• On Tuesday, January 6th, Alexandra Balcom sold 3,181 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total value of $309,065.96.
• On Monday, December 8th, Alexandra Balcom sold 7,084 shares of Nuvalent stock. The shares were sold at an average price of $110.32, for a total value of $781,506.88.
• On Monday, November 17th, Alexandra Balcom sold 20,000 shares of Nuvalent stock. The stock was sold at an average price of $99.45, for a total value of $1,989,000.00.
• On Tuesday, November 18th, Alexandra Balcom sold 729 shares of Nuvalent stock. The shares were sold at an average price of $104.26, for a total value of $76,005.54.
• On Wednesday, October 15th, Alexandra Balcom sold 1,683 shares of Nuvalent stock. The shares were sold at an average price of $85.57, for a total value of $144,014.31.
• On Monday, October 13th, Alexandra Balcom sold 20,000 shares of Nuvalent stock. The stock was sold at an average price of $88.51, for a total transaction of $1,770,200.00.

Nuvalent Trading Up 9.9%

Shares of NASDAQ NUVL traded up $9.62 during midday trading on Wednesday, reaching $106.82. The company’s stock had a trading volume of 895,694 shares, compared to its average volume of 779,373. The stock has a 50 day simple moving average of $102.57 and a 200-day simple moving average of $88.78. The stock has a market capitalization of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32. Nuvalent, Inc. has a fifty-two week low of $55.53 and a fifty-two week high of $112.88.

Nuvalent (NASDAQ:NUVL) last released its earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same quarter last year, the company earned ($1.28) EPS. As a group, equities analysts anticipate that Nuvalent, Inc. will post -3.86 EPS for the current year.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Analyst Ratings Changes

NUVL has been the subject of several recent research reports. Cantor Fitzgerald began coverage on Nuvalent in a research report on Wednesday, October 15th. They set an “overweight” rating and a $135.00 price target for the company. Piper Sandler upped their price objective on Nuvalent from $112.00 to $128.00 and gave the stock an “overweight” rating in a research note on Monday, October 27th. Barclays set a $152.00 price objective on Nuvalent in a report on Monday, November 17th. JPMorgan Chase & Co. lowered their target price on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $125.00 price target (up previously from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. Fifteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $138.33.

Hedge Funds Weigh In On Nuvalent

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in shares of Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Nuvalent during the 3rd quarter worth about $38,000. Eastern Bank acquired a new position in Nuvalent in the 3rd quarter valued at about $52,000. Persistent Asset Partners Ltd bought a new position in Nuvalent in the 2nd quarter valued at about $88,000. Finally, Farther Finance Advisors LLC raised its holdings in Nuvalent by 9,230.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after acquiring an additional 1,200 shares during the period. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.